AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12492193
Drug: Mesalamine 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 2.4 g/day
Trial: 7649071
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with trihexyphenidyle (group III)
Trial: 2539772
Drug: Thymostimulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (1 mg/Kg i.m., days 7-14 of every cycle)
Trial: 334808
Drug: Phenytoin 100
RxNorm normalized name: phenytoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 100 mg every 8 hours for two weeks
Trial: 26865602
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg twice a day for 2 months with prayer (group B)
Trial: 26865602
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg twice a day for 2 months (group A)
Trial: 23608721
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU of daily vitamin D3
Trial: 23608721
Drug: 1,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 IU of daily vitamin D3
Trial: 19793473
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics (group 2)
Trial: 12958610
Drug: Triacylglycerol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triacylglycerol infusion [1.5 ml/min]/heparin [0.2 IU/(kg.min)] (LIP)
Trial: 12958610
Drug: Saline/heparin (HEP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/heparin (HEP)
Trial: 9177404
Drug: Calcium Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Supplementation (CS; 500 mg/day)
Trial: 3522483
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of acetylsalicylic acid
Trial: 23620943
Drug: TCM herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM herbal cupping therapy
Trial: 23620943
Drug: Thermal compressing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal compressing therapy
Trial: 23620943
Drug: Mecobalamine (western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecobalamine (western medicine)
Trial: 21480107
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg of hepatitis B vaccine intramuscularly at birth (0), 2 and 9‐12 months of life
Trial: 21480107
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine at 0, 1 and 6 months of life
Trial: 11468543
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg once daily)
Trial: 24576196
Drug: Titration (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration (15 mcg/m(2) s.c. three times weekly during week 1, 30 mcg/m(2) s.c. three times weekly during week 2, followed by 50 mcg/m(2) s.c. three times weekly during week 3)
Trial: 24576196
Drug: No Titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Titration (full 50 mcg/m(2) s.c. three times weekly for 3 weeks)
Trial: 24576196
Drug: Titration
RxNorm normalized name: Rebif Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration
Trial: 24576196
Drug: Titration and
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration and No Titration
Trial: 16549837
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 plus aprinocarsen 2 mg/kg/d as continuous infusion for 14 days
Trial: 16549837
Drug: Gemcitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1
Trial: 9266531
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 administered as a meal (30 mg/person)
Trial: 9266531
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 administered as capsules (30 mg/person)
Trial: 9266531
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (both forms of administration)
Trial: 22158731
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)
Trial: 22158731
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg phentermine/92 mg controlled-release topiramate (15/92)
Trial: 18512557
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg amikacin administered at 3-4 postburn hours (A group)
Trial: 18512557
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg amikacin administered at 10 postburn hours (B group)
Trial: 18512557
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg amikacin administered at 20 postburn hours (C group)
Trial: 18512557
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg amikacin administered at 30 postburn hours (D group)
Trial: 12100328
Drug: Na-P preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-P preparation
Trial: 12100328
Drug: PEG preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG preparation
Trial: 9842950
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (titrated to a maximum of 200 mg/d for 12 weeks)
Trial: 8128938
Drug: IV bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus of p‐aminohippurate (PAH) 10 mg/kg
Trial: 8128938
Drug: IV bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus of phenolsulfonphthalein (PSP) 1 mg/kg
Trial: 8128938
Drug: Standard constant‐rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard constant‐rate IV infusion of PAH
Trial: 2918184
Drug: Hyposensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization therapy with Gi-rep (MW 106,000)
Trial: 2918184
Drug: Hyposensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization therapy with Ei-M (MW 22,800)
Trial: 2918184
Drug: Hyposensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization therapy with DIIIa (MW 9980)
Trial: 2918184
Drug: Hyposensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization therapy (all antigens)
Trial: 2918184
Drug: Hyposensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyposensitization therapy
Trial: 791105
Drug: mannitol (M),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mannitol (M), 1 g/kg
Trial: 791105
Drug: amphotericin B,
RxNorm normalized name: Amphotericin B, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amphotericin B, 1 mg/kg
Trial: 11557169
Drug: Physostigmine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine augmentation
Trial: 29855372
Drug: Alpha Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha Brain nootropic supplement (1925 mg, 3 pills per day: 2 pills at breakfast, 1 pill at dinner)
Trial: 29855372
Drug: Alpha Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha Brain nootropic supplement
Trial: 27694266
Drug: VKA (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA (Vitamin K Antagonists)
Trial: 22035647
Drug: Preoperative counseling
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative counseling (Treatment group)
Trial: 20136176
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant (CI) listeners
Trial: 16351674
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (2 cc of 10 mg)
Trial: 16351674
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 cc)
Trial: 12851665
Drug: Enhanced Pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Pharmaceutical Care (EC)
Trial: 10349117
Drug: Intravenous diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diphenhydramine (DPH)
Trial: 10349117
Drug: Oral diphenhydramine
RxNorm normalized name: diphenhydramine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diphenhydramine (DPH)
Trial: 10349117
Drug: Functional score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional score after oral DPH
Trial: 2019162
Drug: Albuterol, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol, 90 micrograms by inhalation four times a day
Trial: 19224365
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment (EBT) for child PTSD
Trial: 12063523
Drug: Nasal glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 microg/d)
Trial: 12063523
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of montelukast (10 mg/d) and antihistamine (loratadine, 10 mg/d)
Trial: 9802705
Drug: Biodegradable controlled-release
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable controlled-release delivery system containing doxycycline hyclate (8.5% w/w)
Trial: 9802705
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (200 mg on day 0, then 100 mg/day for 7 days)
Trial: 404157
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) 50 U i.v. followed by 2 U/min infusion for 60-90 min
Trial: 17692922
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg single dose)
Trial: 17692922
Drug: Boric acid
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boric acid suppositories (600 mg daily for 14 days)
Trial: 15155324
Drug: IV parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IV parecoxib 40 mg followed by oral valdecoxib 40 mg
Trial: 9862047
Drug: Neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoendocrine therapy (mitozantrone and methotrexate (+/‐ mitomycin‐C) combined with tamoxifen)
Trial: 9862047
Drug: Neoadjuvant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and adjuvant therapy
Trial: 7832334
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg orally)
Trial: 7832334
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg/70 kg intravenously)
Trial: 7832334
Drug: Propofol (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (70 mg/70 kg intravenously)
Trial: 226565
Drug: Sotalol 960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 960 mg
Trial: 19296248
Drug: Preventive enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive enteral nutrition (EN) - 1000 ml Nutrison Multi Fibre (4184 kJ/L) for 3 days before surgery
Trial: 15170367
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg single dose
Trial: 15170367
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg multiple doses (once monthly)
Trial: 15170367
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg (once monthly)
Trial: 9301991
Drug: Clarithromycin-omeprazole dual
RxNorm normalized name: AMOXICILLIN/CLARITHROMYCIN/OMEPRAZOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-omeprazole dual therapy
Trial: 9301991
Drug: Omeprazole therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole therapy alone
Trial: 24942409
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 1.4 ± 0.5 mg/kg
Trial: 24942409
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (MPH) 52.4 ± 16.6 mg
Trial: 21914270
Drug: Protein-free calf
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-free calf blood extract eye gel (3 times per day for three months)
Trial: 21914270
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no drug treated group)
Trial: 11174292
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium thiosulfate solution spray
Trial: 11174292
Drug: Maalox (aluminum‐magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maalox (aluminum‐magnesium hydroxide gel)
Trial: 8948741
Drug: Gelatine infusion
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine infusion with 3.5% urea bridges during normovolemic intentional hemodilution
Trial: 31009034
Drug: Albuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2 actuations, 200 μg)
Trial: 25551626
Drug: Hippotherapy (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (30 minutes twice weekly for 8 consecutive weeks)
Trial: 19085221
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy session
Trial: 19085221
Drug: Videotape about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotape about art therapy
Trial: 17045803
Drug: Concurrent motor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent motor task (carrying a tray with marbles)
Trial: 17045803
Drug: Concurrent motor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent motor task (carrying a tray without marbles)
Trial: 17045803
Drug: Walking alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking alone (no concurrent task)
Trial: 15090936
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg/day for days 1-14; 100 or 200 mg/day for days 15-28)
Trial: 11466245
Drug: Carteolol alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol alginate once daily
Trial: 11466245
Drug: Standard carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard carteolol solution, twice daily
Trial: 2846002
Drug: Corticosteroids (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (oral or parenteral)
Trial: 30578392
Drug: Anlotinib therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib therapy
Trial: 28245383
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (hydroxyurea plus IFN-alpha)
Trial: 24929889
Drug: Progestogen-only pills
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen-only pills (POPs)
Trial: 19580584
Drug: MEL 308
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL 308 nm once-weekly and oral vitamin E
Trial: 19580584
Drug: MEL 308
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL 308 nm once-weekly combined with khellin 4% ointment and oral vitamin E
Trial: 19580584
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E (control group)
Trial: 17924873
Drug: 303 Algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 303 Algorithm group (self-titration dosing guideline)
Trial: 15356670
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (herbal formulation containing ephedrine, caffeine, and other ingredients)
Trial: 11368462
Drug: Placebo 5
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg
Trial: 9529020
Drug: MAID chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAID chemotherapy (doxorubicin, dacarbazine, ifosfamide, and mesna)
Trial: 9529020
Drug: MAID chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAID chemotherapy
Trial: 2657839
Drug: Buspirone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (mean dose 29.5 mg/day)
Trial: 2657839
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean dose 140 mg/day)
Trial: 24535937
Drug: Decitabine +
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine + NY-ESO-1 vaccine + doxorubicin liposome chemotherapy
Trial: 18793913
Drug: Sublingual triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual triazolam 0.25 mg
Trial: 15728060
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of epidural saline
Trial: 12503978
Drug: Candesartan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (16 mg daily)
Trial: 10841179
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg) plus Vitamin D (800 IU)
Trial: 8853667
Drug: Immediate-release acetaminophen
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release acetaminophen (IR APAP)
Trial: 8422668
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human erythropoietin (r‐hEPO) administration (3000 IU, 12 cases; 6000 IU, 14 cases), three times a week
Trial: 8422668
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human erythropoietin (r‐hEPO) administration
Trial: 24525155
Drug: HTUPA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTUPA (25 mg bolus)
Trial: 20116842
Drug: Interrupted sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted sedation (20 mg/mL propofol for 48 h, 1 mg/mL midazolam thereafter) (n=70, control group)
Trial: 17573510
Drug: Posaconazole 800
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 800 mg/d, administered in divided doses for 34 to 365 days
Trial: 17573510
Drug: Posaconazole treatment
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole treatment
Trial: 17573510
Drug: Posaconazole treatment
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole treatment for >or= 12 months
Trial: 12242060
Drug: Olanzapine (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (initiated at 2.5 mg/day, with increases allowed every 3 to 4 days up to a maximum of 15 mg/day)
Trial: 8580279
Drug: Lintopride 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintopride 0.1 mg/kg
Trial: 8580279
Drug: Lintopride 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintopride 0.3 mg/kg
Trial: 8580279
Drug: Lintopride 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintopride 0.5 mg/kg
Trial: 2571184
Drug: Secretin and
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin and Somatostatin (combined infusion)
Trial: 31378318
Drug: Cefiderocol 2-g
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2-g dose (therapeutic)
Trial: 31378318
Drug: Cefiderocol 4-g
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 4-g dose (supratherapeutic)